Suscribirse

Penile calciphylaxis: A retrospective case-control study - 12/10/21

Doi : 10.1016/j.jaad.2020.05.042 
Colleen Gabel, BS a, Teja Chakrala, BS b, Radhika Shah, MD, PharmD c, Melissa J. Danesh, MD d, Allison S. Dobry, MD e, Anna Cristina Garza-Mayers, MD, PhD d, Lauren N. Ko, MD, MEd d, Emily Nguyen, BS a, Jessica St. John, MD, MBA, MPH f, Andrew C. Walls, MD g, Sagar U. Nigwekar, MD, MMSc h, Philip I. Song, MD i, Daniela Kroshinsky, MD, MPH a,
a Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts 
b Narayana Medical College and Hospital, Nellore, India 
c Department of Dermatology, Robert Wood Johnson Medical School, New Brunswick 
d Department of Dermatology, Harvard Medical School, Boston, Massachusetts 
e Department of Dermatology, University of California, Irvine School of Medicine, Irvine, California 
f Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts 
g Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 
h Department of Nephrology, Massachusetts General Hospital, Boston, Massachusetts 
i Department of Dermatology, Palo Alto Medical Foundation, Palo Alto, California 

Correspondence to: Correspondence and reprint requests to: Daniela Kroshinsky, MD, MPH, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, 2nd Floor, Boston, MA 02114.Department of DermatologyMassachusetts General Hospital50 Staniford St2nd FloorBostonMA02114

Abstract

Background

Calciphylaxis is a rare disorder characterized by skin necrosis caused by calcium deposition within vessels, thrombosis, and subsequent tissue ischemia. Penile involvement may rarely occur.

Objective

To identify risk factors, diagnosis, management, and mortality of patients with penile calciphylaxis.

Methods

A retrospective medical record review was conducted of 16 patients with penile calciphylaxis treated at 2 large urban tertiary care centers between January 2001 and December 2019. A control group of 44 male patients with nonpenile calciphylaxis at the same institution was included.

Results

The median survival of patients with penile calciphylaxis was 3.8 months (interquartile range, 27.0 months). Mortality was 50% at 3 months and 62.5% at 6 months for penile calciphylaxis, and 13.6% at 3 months and 29.5% at 6 months for controls (P = .008). Patients with penile calciphylaxis were less likely to be obese (P = .04) but more likely to have hyperparathyroidism (P = .0003) and end-stage renal disease (P = .049).

Limitations

Retrospective study design and small sample size.

Conclusions

This study further defines the disease course of penile calciphylaxis, which has high mortality. Imaging may be used to aid diagnosis. Risk factors include end-stage renal disease, hyperparathyroidism, and normal body mass index.

El texto completo de este artículo está disponible en PDF.

Key words : calciphylaxis, diagnosis, management, outcomes, penile, risk factors

Abbreviations used : ESRD, STS


Esquema


 Funding sources: None.
 Conflicts of interest: Dr Nigwekar has received grant support from Hope Pharmaceuticals. Authors Gabel, Chakrala, and Nguyen and Drs Shah, Danesh, Dobry, Garza-Mayers, Ko, St. John, Walls, Song, and Kroshinsky have no conflicts of interest to declare.
 IRB approval status: Reviewed and approved by Partners Institutional Review Board: 2018P000551


© 2020  American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 85 - N° 5

P. 1209-1217 - novembre 2021 Regresar al número
Artículo precedente Artículo precedente
  • Complete and transparent reporting of primary end points of randomized trials in the dermatology literature: A comparison of registered and published primary end points
  • Do-Yeop Kim, Sohee Oh, Hyun-Sun Yoon
| Artículo siguiente Artículo siguiente
  • Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017
  • Shayan Cheraghlou, Kalman L. Watsky, Jeffrey M. Cohen

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.